Effects of bifidobacterium combined with piverium bromide on clinical efficacy,intestinal flora and immune function in patients with irritable bowel syndrome
Objective To investigate the clinical efficacy of bifidobacterium combined with pivilium bromide in the treatment of irritable bowel syndrome(IBS).Methods A total of 150 IBS patients admitted to the Second People's Hospital of Xin-yang City from May 1,2021 to May 31,2023 were selected and divided into pivillium bromide group and bifidobacterium combined group by random number table method,with 75 cases in each group.The pivillium bromide group was given pivillium bromide(oral administration,50 mg/time,3 times/day),and the bifidobacterium combination group was given bifidobacterium triple viable capsule(oral administration,3 capsules/time,2 times/day)combined with pivillium bromide treatment.The clinical efficacy was compared between the two groups.Stool trait score was evaluated by Bristol stool form scale,stool frequency was recorded,and positive numbers of bifidobacterium,Escherichia coli,Lactobacillus and Enterococcus faecalis were identified by Gram staining after bacterial population culture.Immunoglobulin(Ig)M,IgG and IgA were detected by immune single diffusion method.Results After treatment,the total effective rate of bifidobac-terium combined group was 94.67％,which was higher than that of piverium bromide group 84.00％,the difference was statistically significant(x2=4.478,P=0.034).After treatment,the stool frequency in bifidobacterium combination group was(1.52±0.64)times/d,which was less than that in piviterium bromide group(1.85±0.67)times/d,and the stool trait score was(3.09±0.92)points,which was higher than that in piviterium bromide group(2.29±0.87)points,the differences were statistically significant(F=5.280,F=14.963,All P＜0.05);after treatment,the numbers of bifidobacterium and Lactobacillus in bifidobacterium combination group were(9.78±1.30)CFU/g and(9.35±0.98)CFU/g,respectively,which were higher than those in piverium bromide group(8.69±0.89)CFU/g and(8.47±1.25)CFU/g,the numbers of Escherichia coli and Enterococcus faecalis were(6.29±0.87)CFU/g and(6.13±0.89)CFU/g,respectively,which were lower than those in piverium bromide group(7.34±0.90)CFU/g and(6.89±1.05)CFU/g,the differences were statistically significant(F values were 17.896,11.421,26.454,11.902,all P＜0.001);after treatment,IgM,IgG and IgA in bifidobacterium combination group were(1.60±0.18)g/L,(15.08±1.14)g/L and(1.85±0.27)g/L,respectively,which were higher than those in piverium bromide group(1.41±0.24)g/L,(13.89± 1.27)g/L and(1.49±0.20)g/L,the differences were statistically significant(F values were 17.040,19.815,43.789,all P＜0.001).Conclusion Bifidobacterium combined with piverium bromide is effective in the treatment of IBS patients,which can effectively reduce stool frequency,improve stool characteristics,improve intestinal flora disorder,enhance im-mune function,and contribute to the recovery of patients'disease.
bifidobacterium triple viable capsulepiverium bromideirritable bowel syndromeimmune function
NETL
NSTL
万方数据
